Viracta Therapeutics (VIRX) Competitors $0.02 0.00 (-8.11%) As of 10:28 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. GRI, SCNI, PTN, EVAX, AWH, VCNX, APVO, ELAB, GLMD, and TNFAShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include GRI Bio (GRI), Scinai Immunotherapeutics (SCNI), Palatin Technologies (PTN), Evaxion Biotech A/S (EVAX), Aspira Women's Health (AWH), Vaccinex (VCNX), Aptevo Therapeutics (APVO), Elevai Labs (ELAB), Galmed Pharmaceuticals (GLMD), and TNF Pharmaceuticals (TNFA). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. GRI Bio Scinai Immunotherapeutics Palatin Technologies Evaxion Biotech A/S Aspira Women's Health Vaccinex Aptevo Therapeutics Elevai Labs Galmed Pharmaceuticals TNF Pharmaceuticals GRI Bio (NASDAQ:GRI) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation. Do analysts rate GRI or VIRX? GRI Bio currently has a consensus target price of $115.50, suggesting a potential upside of 9,140.00%. Viracta Therapeutics has a consensus target price of $4.06, suggesting a potential upside of 23,797.06%. Given Viracta Therapeutics' higher probable upside, analysts clearly believe Viracta Therapeutics is more favorable than GRI Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer GRI or VIRX? Viracta Therapeutics received 25 more outperform votes than GRI Bio when rated by MarketBeat users. However, 100.00% of users gave GRI Bio an outperform vote while only 70.73% of users gave Viracta Therapeutics an outperform vote. CompanyUnderperformOutperformGRI BioOutperform Votes4100.00% Underperform VotesNo VotesViracta TherapeuticsOutperform Votes2970.73% Underperform Votes1229.27% Does the media favor GRI or VIRX? In the previous week, GRI Bio had 2 more articles in the media than Viracta Therapeutics. MarketBeat recorded 2 mentions for GRI Bio and 0 mentions for Viracta Therapeutics. Viracta Therapeutics' average media sentiment score of 0.00 beat GRI Bio's score of -0.17 indicating that Viracta Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment GRI Bio Neutral Viracta Therapeutics Neutral Which has more risk & volatility, GRI or VIRX? GRI Bio has a beta of -1.67, meaning that its stock price is 267% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Do institutionals & insiders have more ownership in GRI or VIRX? 34.0% of GRI Bio shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 0.1% of GRI Bio shares are held by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GRI or VIRX more profitable? GRI Bio's return on equity of -289.05% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GRI BioN/A -289.05% -165.01% Viracta Therapeutics N/A -1,899.61%-114.21% Which has stronger earnings & valuation, GRI or VIRX? GRI Bio is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGRI BioN/AN/A-$13.04M-$11.56-0.11Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.02 SummaryViracta Therapeutics beats GRI Bio on 8 of the 14 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$676,000.00$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.029.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.056.406.744.50Net Income-$51.06M$143.98M$3.23B$248.32M7 Day PerformanceN/A1.90%1.49%-0.03%1 Month PerformanceN/A4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics1.1908 of 5 stars$0.02-8.1%$4.06+23,797.1%-97.6%$676,000.00N/A-0.0220Gap UpGRIGRI Bio2.413 of 5 stars$1.40-6.7%$115.50+8,150.0%-98.5%$2.68MN/A-0.121Earnings ReportGap UpHigh Trading VolumeSCNIScinai ImmunotherapeuticsN/A$2.82-3.1%N/A-22.4%$2.63M$658,000.00-0.0120PTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350,000.00-0.0630Analyst ForecastGap DownHigh Trading VolumeEVAXEvaxion Biotech A/S2.1747 of 5 stars$1.71-1.8%$10.00+484.8%-90.3%$2.44M$3.34M-1.1860News CoverageUpcoming EarningsAWHAspira Women's Health0.9375 of 5 stars$0.08-12.5%$5.50+6,607.3%-97.0%$2.44M$9.18M-0.07110High Trading VolumeVCNXVaccinexN/A$0.92-11.3%N/A-87.8%$2.40M$388,000.00-0.0240Gap DownAPVOAptevo Therapeutics2.1249 of 5 stars$0.31-3.1%$10,952.00+3,532,803.2%-100.0%$2.38M$3.11M0.0050Negative NewsEarnings ReportGap DownELABElevai Labs0.4881 of 5 stars$2.52+2.0%N/A-99.7%$2.23M$2.45M-0.0418News CoveragePositive NewsGLMDGalmed Pharmaceuticals0.4141 of 5 stars$1.28+7.6%N/A-70.7%$2.12MN/A-0.0820Upcoming EarningsGap DownTNFATNF PharmaceuticalsN/A$0.20+5.5%N/AN/A$2.02MN/A-0.036Earnings ReportHigh Trading Volume Related Companies and Tools Related Companies GRI Alternatives SCNI Alternatives PTN Alternatives EVAX Alternatives AWH Alternatives VCNX Alternatives APVO Alternatives ELAB Alternatives GLMD Alternatives TNFA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIRX Stock Free VIRX Stock Alerts